223 related articles for article (PubMed ID: 33272645)
1. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Straubhar AM; Wolf JL; Zhou MQC; Iasonos A; Cham S; Wright JD; Long Roche K; Chi DS; Zivanovic O
Gynecol Oncol; 2021 Feb; 160(2):438-444. PubMed ID: 33272645
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
[TBL] [Abstract][Full Text] [Related]
3. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
Manning-Geist B; Cathcart AM; Sullivan MW; Pelletier A; Cham S; Muto MG; Del Carmen M; Growdon WB; Sisodia RC; Berkowitz R; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1356-1362. PubMed ID: 34518239
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; van Doorn HC; van Beekhuizen HJ
Int J Gynecol Cancer; 2023 Feb; 33(2):263-270. PubMed ID: 36600504
[TBL] [Abstract][Full Text] [Related]
5. Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.
Nieuwenhuyzen-de Boer GM; Gerestein CG; Eijkemans MJ; Burger CW; Kooi GS
Eur J Gynaecol Oncol; 2016; 37(1):63-8. PubMed ID: 27048112
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
Xu Y; Jia Y; Zhang Q; Du Y; He Y; Zheng A
Gynecol Oncol; 2021 Feb; 160(2):610-618. PubMed ID: 33221022
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
8. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
[TBL] [Abstract][Full Text] [Related]
9. Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
Kranawetter M; Ataseven B; Grimm C; Schneider S; Riss S; Alesina P; Prader S; Walz MK; Harpain F; Stift A; Heitz F; Reinthaller A; Polterauer S; Harter P; du Bois A
Gynecol Oncol; 2019 Sep; 154(3):577-582. PubMed ID: 31235241
[TBL] [Abstract][Full Text] [Related]
10. Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
Jiang C; Li Z
Gynecol Oncol; 2021 Aug; 162(2):339-344. PubMed ID: 34147283
[TBL] [Abstract][Full Text] [Related]
11. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery.
Barber EL; Rutstein S; Miller WC; Gehrig PA
Gynecol Oncol; 2015 Dec; 139(3):401-6. PubMed ID: 26432038
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction.
Mohammad A; Ainio C; Narasimhulu DM; McGree M; Weaver AL; Kumar A; Garbi A; Mariani A; Aletti G; Multinu F; Langstraat C; Cliby W
Int J Gynecol Cancer; 2023 May; 33(5):727-733. PubMed ID: 36750269
[TBL] [Abstract][Full Text] [Related]
13. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; Niehot CD; van Beekhuizen HJ
J Gynecol Oncol; 2022 Jul; 33(4):e53. PubMed ID: 35712967
[TBL] [Abstract][Full Text] [Related]
15. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
16. Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
Hasselgren E; Hertzberg D; Camderman T; Björne H; Salehi S
Gynecol Oncol; 2021 May; 161(2):402-407. PubMed ID: 33715894
[TBL] [Abstract][Full Text] [Related]
17. Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.
Xu Z; Becerra AZ; Justiniano CF; Aquina CT; Fleming FJ; Boscoe FP; Schymura MJ; Sinno AK; Chaoul J; Morrow GR; Minasian L; Temkin SM
J Surg Res; 2020 Feb; 246():34-41. PubMed ID: 31561176
[TBL] [Abstract][Full Text] [Related]
18. Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
Di Donato V; Di Pinto A; Giannini A; Caruso G; D'Oria O; Tomao F; Fischetti M; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2021 Apr; 161(1):4-10. PubMed ID: 33223220
[TBL] [Abstract][Full Text] [Related]
19. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
20. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
